Treatment News : CD4 Cell’s Main Coreceptor Is Mapped in High Resolution

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 18, 2013

CD4 Cell’s Main Coreceptor Is Mapped in High Resolution

For the first time, researchers have documented the microscopic structure of the main CD4 coreceptor, called the CCR5 receptor, that HIV binds to in order to begin its entry into the immune cell, the Los Angeles Times reports. Publishing their findings in the journal Science, Chinese and American researchers studied the action of the antiretroviral (ARV) Selzentry (maraviroc), which is a CCR5 receptor antagonist that binds to the CD4 coreceptor, blocking HIV.

The research team had already diagrammed CXCR4, which is the other coreceptor HIV uses to enter CD4 cells, albeit less often.

In the study, the investigators let Selzentry bind to an engineered CCR5 coreceptor before purifying and crystallizing the result. Studying the structure at a very high resolution, they found that the drug binds to a separate site on the coreceptor than either HIV or the natural immune proteins called chemokines.

The scientists were able to discover how mutated versions of HIV are able to evade CCR5 inhibitors: When the coreceptor forms an atypical dome shape, it is less likely to bond to the drug, but is still open to linking with HIV.

Details on the structural differences between the CXCR4 and CCR5 coreceptors were also uncovered—findings that might lead to an understanding of why HIV is inclined toward one over the other.

All of these insights have the potential to improve existing ARVs that focus on blocking the virus’s connection to CCR5, in addition to spurring research into new therapies.

To read the LA Times story, click here.

To read two different releases on the research, click here and here.

To read the study abstract, click here.

Search: HIV, coreceptor, CD4, high resolution, CCR5, CXCR4, Selzentry, maraviroc, Science, Los Angeles Times, chemokines.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    Sloan1
    Dallas
    Texas


    latinpozdallas
    Dallas
    Texas


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.